Key Takeaways
- Record revenue, margin expansion: FY23 delivered highest ever revenue and EBITDA, with gross margin expanding 480 bps YoY driven by new launches and mix change, against a weak prior-year quarter that included a one-time COVID inventory provision.
- North America crosses $200 mn quarter: The U.S. business hit its highest ever quarterly revenue, powered by traction in the differentiated portfolio, and management signaled fairly significant growth for FY24 despite two asset delays.
- Facility risk is the central bottleneck: Generic Advair, nanopaclitaxel and a third respiratory asset are all being derisked to alternative sites while the company waits on Goa remediation and Indore classification, a process that adds roughly 12 months to launch timelines.
- India engine stays on, consumer health resets: One India grew 16% ex-COVID on an extended flu season and field force expansion, while the consumer health division targets mid-teen EBITDA in FY24 after a seasonal Q4 trough.
- What to watch next quarter: The Indore facility classification expected in May, the Goa CAPA completion by end of Q1, and whether the U.S. base business sustains the $190–195 mn quarterly trajectory.
U.S. Business & the Derisking Imperative
- Record quarter, volume-led: North America revenue crossed $200 mn in Q4, with volume growth continuing strong and no significant change in market pricing dynamics. Price hike impact is expected to begin in Q1 but show real effect in Q2 and Q3.
- Base business trajectory: Management guided a $190–195 mn quarterly range as a good trajectory for the base business, with FY24 growth expected over FY23's $733 mn despite two asset delays, driven by peptide products ramping up.
- Revlimid variance explained: Differences in volume versus competitors stem from each company's specific arrangement with the branded player, with some arrangements allowing more volume than Cipla's. Volume numbers may also lag prescription numbers because the product moves through specialty pharmacies.
- Lanreotide share: Management expects a gradual rise in market share over the next couple of quarters, not a sudden increase.
The derisking pipeline
- Three assets in flight: Generic Advair is being derisked to another in-house facility (not in India), nanopaclitaxel to a partner CMO site, and a third respiratory asset to Cipla's U.S. facility. For most products, the derisking timeline averages roughly 12 months.
- Advair specifics: The ANDA has cleared all other FDA questions and is solely dependent on facility approval. Derisking will take slightly longer than 12 months, and management declined to name the specific site or quantify the cost, stating only that "we will still be very competitive."
- Nanopaclitaxel specifics: Exhibit batches are being taken at the partner site, with supply expected from two sites by FY25. Management sees a good chance of launch within 12 months.
- Respiratory filing strategy going forward: Every product filed will have derisking built in from day one, with big products filed from two sites rather than one.
Vohra: "The value stays intact as no new generic is expected before we launch."
Facility Status & Remediation
- Goa: CAPA completion is expected by end of Q1 FY24, with reinspection targeted for Q3. Remediation costs, which include capex, opex and consultant costs, are already embedded in Q3 and Q4 numbers and no spike is expected from current levels. Costs are expected to go down after reinspection.
- Indore: The facility completed a CGMP audit resulting in 0483 observations. Final classification is expected by mid-May. Management stated there is no risk to commercializing the product portfolio, and if the outcome is adverse, Advair manufacturing will happen elsewhere; if the outcome is fine, Cipla is ready to commercialize completely from India.[14-15]
- Fall River: The U.S. facility completed a CGMP audit with 0483 observations and received approval to produce respiratory assets at the site.
- ANDAs sensitivity: When asked how many of the 43 pending ANDAs originate from Indore and Goa, management deflected, stating both sites do not have huge sensitivity to the launch calendar for the next 2–3 years.
One India & Consumer Health
- One India momentum: The business expanded market share in a traditionally weak seasonal quarter, delivering 16% ex-COVID growth driven by an extended countrywide flu season. Management hopes to continue the market-beating growth seen over the last two years.
- Tier dynamics: Tier 2 to 6 towns are seeing deepening of healthcare, feeding respiratory and anti-infective products, while Tier 1 towns are seeing therapy upscaling, for example from oral diabetes drugs to injectable obesity and diabetes treatments.
- Field force expansion: Over 800 people have been added in the last two years, with plans to add another 1,000-plus between FY23 and FY24. New MRs take 6–9 months from hiring to become productive.
- Galvus perpetual license: Cipla signed a perpetual license agreement with Novartis for Galvus and its combination brands, which had sales of roughly ₹270 crores MAT March 2023. Management believes it can increase sales year-on-year.
- Consumer health seasonality: Revenue dropped from roughly ₹300 crores to ₹47 crores sequentially, a seasonal pattern driven by a portfolio weighted toward summer products like ORS.
- Consumer health profitability: The objective is to reach the higher range of mid-teen to double-digit EBITDA in the current year, then graduate toward the company average over the next 2–3 years.
Vohra: "We are seeing a pretty strong Tier 2 to 6 growth, and that is feeding some of our products that are in the areas of respiratory and anti-infectives because those are the type of products that will deepen in India."
Margins & Cost Structure
- Gross margin expansion: The 480 bps YoY improvement was driven by contribution from new launches and overall mix change, with the comparison helped by a one-time COVID inventory provision charge in Q4 last year.
- Full-year EBITDA: The 22% margin subsumes lower-than-anticipated SAGA performance, a high inflationary market, higher R&D spend, and certain COVID provisioning. Management is targeting 22% or thereabout for FY24.
- R&D spend: Investments were 15% higher YoY, driven by ongoing clinical trials on differentiated assets and the biosimilar JV contribution. Spend is expected to continue in the 6%–6.5% range in FY24.
- Depreciation increase: Rose from ₹270 crores to ₹346 crores due to impairments in intangible assets.
- NLEM pricing: Not expected to influence growth significantly, as the impact is balanced via allowed price increases and continued volume growth.
Capital Allocation & Portfolio Strategy
- India first: India is the top priority for disproportionate capital allocation, given the growth available. Bolt-on acquisitions in Africa, the U.S., or Europe for facilities, assets or products come next.
- In-licensing logic: Management prefers big brand franchises that can be grown faster, because smaller brands do not justify the lower margin structure that comes with in-licensing.
- South Africa: New launches in the private market are expected to offset reduction in tender business and margin pressures, with growth and margin focus targeted for FY24.
- Scapho partnership: Cipla entered a strategic partnership to market and distribute Scapho, a human IgG1 monoclonal antibody for psoriasis.
- Endura MASS acquisition: Cipla Health acquired the nutritional supplement brand Endura MASS.
Vohra: "If you look at our overall capital allocation priority, I think India continues to be our priority. So the whole -- the disproportionate part of capital, we would look to invest in India for the growth that is available out here."
Pipeline & Respiratory Strategy
- Three differentiated products: Currently undergoing clinical trials with filings targeted in FY24.
- Symbicort: Expected to file by Q4 of the current year.
- QR (respiratory asset): Progress is being made but the matter is sub judice in IP court proceedings; management cannot comment further.
- Dulera: Management declined to comment on a generic filing for the U.S., confirming only that it is there for Europe.
- Respiratory filing strategy: Every product filed will have derisking within the filing, with big products filed from two sites.
Vohra: "Our strategy is to try and file every product that we are doing on the respiratory side from 2 sites and not 1."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Indore facility classification | Final FDA classification expected | May 2023 |
| Goa CAPA completion | CAPA completed, reinspection targeted for Q3 | End of Q1 FY24 |
| U.S. base business quarterly run-rate | $190–195 mn trajectory | Ongoing |
| Full-year consolidated EBITDA margin | 22% or thereabout | FY24 |
| R&D spend | 6%–6.5% of revenue | FY24 |
| Consumer health EBITDA margin | Higher range of mid-teen to double-digit | FY24 |
| Consumer health margin graduation | Toward company average | Next 2–3 years |
| Nanopaclitaxel supply from two sites | Two-site supply established | By FY25 |
| Symbicort filing | ANDA submission | Q4 FY24 |
| Three differentiated product filings | Clinical trials ongoing, filings targeted | FY24 |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Revenue | ₹5,739 cr, +9% YoY reported, +14% ex-COVID |
| Full-year revenue | ₹22,753 cr, +5% YoY reported, +11% ex-COVID |
| EBITDA margin | 20%+ reported for Q4; full year 22% reported, 23% adjusted for COVID |
| Gross margin | 64%, +480 bps YoY driven by new launches and mix change |
| Profit after tax | ₹526 cr (9.2% of sales); adjusted PAT ₹708 cr (12.3% of sales) after one-time impairment charge |
| Full-year PAT | ₹2,802 cr reported; adjusted PAT ₹2,984 cr (13.1% of sales) |
| Effective tax rate | 24% adjusted |
| R&D investment | ₹371 cr (6.5% of revenue), +15% YoY; full year ₹1,344 cr |
| North America revenue | $200 mn+ in Q4, first time crossing this threshold; full year $733 mn, +23% YoY |
| U.S. respiratory revenue | $160 mn for FY23 |
| One India franchise growth | 16% ex-COVID in Q4 |
| India consumer franchise annual run-rate | ₹1,000 cr+ |
| Lanreotide market share | 17% |
| ROIC (trailing 12 months) | ~24%, above long-term range of 17%–20% |
| Field force | ~10,000 total, roughly 7,000 MRs and 3,000 others; grew by 800+ over FY22–23 |